Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
14/06/2024 | 22:05 | Business Wire | Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:RVNC | Revance Therapeutics Inc |
28/05/2024 | 22:05 | Business Wire | Revance to Participate in Upcoming Investor Conferences | NASDAQ:RVNC | Revance Therapeutics Inc |
09/05/2024 | 22:33 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:RVNC | Revance Therapeutics Inc |
09/05/2024 | 22:08 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:RVNC | Revance Therapeutics Inc |
09/05/2024 | 22:06 | Business Wire | Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update | NASDAQ:RVNC | Revance Therapeutics Inc |
09/05/2024 | 22:05 | Business Wire | Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia | NASDAQ:RVNC | Revance Therapeutics Inc |
02/05/2024 | 22:05 | Business Wire | Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 | NASDAQ:RVNC | Revance Therapeutics Inc |
12/04/2024 | 14:00 | Business Wire | Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting | NASDAQ:RVNC | Revance Therapeutics Inc |
08/03/2024 | 22:33 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:RVNC | Revance Therapeutics Inc |
05/03/2024 | 23:00 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:RVNC | Revance Therapeutics Inc |
04/03/2024 | 15:25 | Business Wire | Revance Announces Pricing of $100.0 Million Public Offering of Common Stock | NASDAQ:RVNC | Revance Therapeutics Inc |
04/03/2024 | 12:37 | Business Wire | Revance Announces Proposed Public Offering of Common Stock | NASDAQ:RVNC | Revance Therapeutics Inc |
29/02/2024 | 22:36 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:RVNC | Revance Therapeutics Inc |
28/02/2024 | 22:05 | Business Wire | Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update | NASDAQ:RVNC | Revance Therapeutics Inc |
21/02/2024 | 14:01 | Business Wire | Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024 | NASDAQ:RVNC | Revance Therapeutics Inc |
14/02/2024 | 21:45 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:RVNC | Revance Therapeutics Inc |
02/02/2024 | 14:00 | Business Wire | Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology® | NASDAQ:RVNC | Revance Therapeutics Inc |
01/02/2024 | 14:00 | Business Wire | Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference | NASDAQ:RVNC | Revance Therapeutics Inc |
11/01/2024 | 12:18 | IH Market News | Wall Street Highlights: Mastercard’s Financial Rise, Citigroup’s $3.8 Billion Charges, and More | NASDAQ:RVNC | Revance Therapeutics Inc |
08/01/2024 | 14:00 | Business Wire | Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook | NASDAQ:RVNC | Revance Therapeutics Inc |
12/12/2023 | 11:50 | IH Market News | Hasbro Job Cuts, Oracle’s Stock Decline, Google’s Epic Antitrust Loss, and More | NASDAQ:RVNC | Revance Therapeutics Inc |
14/11/2023 | 22:22 | Edgar (US Regulatory) | Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers | NASDAQ:RVNC | Revance Therapeutics Inc |
08/11/2023 | 22:06 | Business Wire | Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update | NASDAQ:RVNC | Revance Therapeutics Inc |
08/11/2023 | 22:05 | Business Wire | Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics | NASDAQ:RVNC | Revance Therapeutics Inc |
01/11/2023 | 13:00 | Business Wire | Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 | NASDAQ:RVNC | Revance Therapeutics Inc |
26/10/2023 | 14:00 | Business Wire | DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions | NASDAQ:RVNC | Revance Therapeutics Inc |
24/10/2023 | 22:05 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:RVNC | Revance Therapeutics Inc |
19/09/2023 | 15:00 | Business Wire | Revance Provides Corporate Update at Investor Day | NASDAQ:RVNC | Revance Therapeutics Inc |
06/09/2023 | 22:21 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:RVNC | Revance Therapeutics Inc |
01/09/2023 | 15:12 | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial ownership | NASDAQ:RVNC | Revance Therapeutics Inc |